We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Arbutus Biopharma Corporation | NASDAQ:ABUS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.07 | 2.58% | 2.78 | 2.77 | 2.82 | 2.82 | 2.70 | 2.71 | 685,435 | 00:31:07 |
British Columbia, Canada
|
|
001-34949
|
|
98-0597776
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
701 Veterans Circle
Warminster, Pennsylvania
|
|
18974
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Shares, without par value
|
|
ABUS
|
|
The Nasdaq Stock Market LLC
|
Proposal 1.
|
The election of eight director nominees named in the Proxy Statement/Circular to serve until the 2021 Annual General Meeting of Shareholders or until their qualified successors have been duly elected or appointed.
|
Nominee
|
|
Votes For
|
|
%
For
|
|
Votes
Withheld
|
|
%
Withheld
|
|
Broker Non-Votes
|
Frank Torti, M.D.
|
|
33,556,859
|
|
96.65
|
|
1,161,457
|
|
3.35
|
|
14,700,271
|
William H. Collier
|
|
33,559,283
|
|
96.66
|
|
1,159,033
|
|
3.34
|
|
14,700,271
|
Daniel Burgess
|
|
34,281,074
|
|
98.74
|
|
437,242
|
|
1.26
|
|
14,700,271
|
Richard C. Henriques
|
|
34,614,462
|
|
99.70
|
|
103,854
|
|
0.30
|
|
14,700,271
|
Keith Manchester, M.D.
|
|
33,184,154
|
|
95.58
|
|
1,534,162
|
|
4.42
|
|
14,700,271
|
Eric Venker, M.D., Pharm.D.
|
|
33,571,000
|
|
96.70
|
|
1,147,316
|
|
3.30
|
|
14,700,271
|
James Meyers
|
|
34,279,455
|
|
98.74
|
|
438,861
|
|
1.26
|
|
14,700,271
|
Andrew Cheng, M.D., Ph.D.
|
|
34,282,648
|
|
98.75
|
|
435,668
|
|
1.25
|
|
14,700,271
|
Proposal 2.
|
The approval of an amendment to the 2016 Plan to (a) increase the aggregate number of common shares authorized for issuance thereunder by 3,000,000 common shares and (b) increase the aggregate number of common shares that may be issued pursuant to incentive stock options granted thereunder by 3,000,000 common shares:
|
Votes For
|
|
%
For
|
|
Votes
Against
|
|
%
Against
|
|
Votes Withheld
|
|
Broker Non-Votes
|
33,930,299
|
|
98.05
|
|
673,707
|
|
1.95
|
|
114,310
|
|
14,700,271
|
Proposal 3.
|
The approval of the 2020 ESPP:
|
Votes For
|
|
%
For
|
|
Votes
Against
|
|
%
Against
|
|
Votes Withheld
|
|
Broker Non-Votes
|
34,396,216
|
|
99.38
|
|
214,485
|
|
0.62
|
|
107,615
|
|
14,700,271
|
Proposal 4.
|
The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020:
|
Votes For
|
|
%
For
|
|
Votes
Withheld
|
|
%
Withheld
|
|
Broker Non-Votes
|
48,517,264
|
|
98.18
|
|
901,323
|
|
1.82
|
|
0
|
1 Year Arbutus Biopharma Chart |
1 Month Arbutus Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions